Non-psychiatric comorbidity associated with Alzheimer's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The burden of medical comorbidity in individuals with Alzheimer's disease is greater than that observed in matched individuals without dementia. This has important implications for all clinicians and healthcare providers who deal with this common condition. The prevalence of vascular risk factors and vascular disease is particularly high. Additionally, associations with a number of other chronic medical conditions have been described, including thyroid disorders, sleep apnoea, osteoporosis and glaucoma. This review gives an overview of evidenced medical (non-psychiatric) comorbidity associated with Alzheimer's disease and briefly explores the underlying mechanisms that may account for these associations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 1×
“Elevated blood pressure causes the blood–brain barrier disruption around the capillaries in the brain which in turn cause the dysfunction of subcortical vessels.(13) This subsequently impairs critical nutrient delivery to the brain, especially glucose which in turn impairs its performance.”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“Epidemiological studies have also demonstrated lower rates of Alzheimer’s disease in rheumatoid arthritis.(81) Non-steroidal anti-inflammatory drugs (NSAIDs) are a mainstay of treatment for arthritis, and theoretical models implicate inflammation as key to Alzheimer’s disease pathogenesis.”
BackgroundMidlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008 · cited 2×
“Evidence shows that elevated blood pressure in midlife is a strong risk factor for Alzheimer’s disease.(7) However, hypotension in later life, defined as a diastolic blood pressure <70 mmHg, has a similar effect.”
BackgroundResultAnstey, K. J., Cherbuin, N., Budge, M., & Young, J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00825.x · Cited by 855 · cited 1×
“risk factor for both Alzheimer’s and vascular dementia,(35,36) though this association may disappear or even become reversed in later life.(35) Obesity results in free fatty acid elevation and inhibition of enzyme metalloprotease, which facilitates clearance of -amyloid and normal insulin signalling.”
BackgroundRisk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547 · cited 1×
“Peripheral hyperinsulinemia seen in type 2 diabetes results in blood–brain barrier dysfunction and decreased insulin transport to the brain.(28,29) Reduced brain insulin signalling causes increased tau phosphorylation and -amyloid levels in a streptozin mouse model of diabetes.”
BackgroundProtective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535 · cited 1×
“COX1 is implicated in the activation of microglia in Alzheimer’s disease, and the theoretical rationale for the use of NSAIDS targeting this enzyme is supported by epidemiological work.(85,88) Some clinical trials have investigated the newer selective COX 2 inhibitors such as celecoxib, finding no benefit.”
BackgroundNSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · cited 3×
“COX1 is implicated in the activation of microglia in Alzheimer’s disease, and the theoretical rationale for the use of NSAIDS targeting this enzyme is supported by epidemiological work.(85,88) Some clinical trials have investigated the newer selective COX 2 inhibitors such as celecoxib, finding no benefit.”
BackgroundResultPetrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., Nelson, J., Davis, D. G., Hardman, J., Foley, D. J., et al. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00106-8 · Cited by 468 · cited 1×
“Second, it triggers an inflammatory response that promotes neuritic plaque formation.(15) Extreme hypoxia has also been shown to cause amyloid precursor protein accumulation and its subsequent cleavage to amyloid.”
Background
Cited by
Calderón‐Larrañaga, A., Vetrano, D. L., Ferrucci, L., Mercer, S. W., Marengoni, A., Onder, G., Eriksdotter, M., & Fratiglioni, L. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12843 · Cited by 408
Comorbidity of dementia: a cross-sectional study of primary care older patients
Poblador-Plou, B., Calderón-Larrañaga, A., Marta-Moreno, J., Hancco-Saavedra, J., Sicras-Mainar, A., Soljak, M., & Prados-Torres, A. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-84 · Cited by 256
Pistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
Dementia care costs and outcomes: a systematic review
Knapp, M., Iemmi, V., & Romeo, R. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3864 · Cited by 126
“Individuals with dementia have an elevated risk of co-morbid conditions (Duthie et al., 2011) and hence could require more medical or social care.”
BackgroundTang, A. S., Oskotsky, T., Havaldar, S., Mantyh, W. G., Bicak, M., Solsberg, C. W., Woldemariam, S., Zeng, B., Hu, Z., Oskotsky, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28273-0 · Cited by 45
“Prior work, largely hypothesis-driven, focused on select comorbidities associated with AD, such as hypertension 16 , vascular disorders 17 , diabetes 18 , obesity 19 , and others 20 – 22 .”
Background
Metadata
- Authors
- Duthie, A., Chew, D., & Soiza, R. L.
- Venue
- QJM
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-18
- Volume
- 104
- Issue
- 11
- Pages
- 913-920
- ISSN
- 0033-5622 (ISSN-L)
- 1460-2725
- 1460-2393
- OpenAlex
- W2142801378
- Cited by
- 95
- References
- 20
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-psychiatric comorbidity associated with Alzheimer's disease. https://app.cochat.ai/papers/10.1093/qjmed/hcr118
- The paper
- Duthie, A., Chew, D., & Soiza, R. L. (2011). Non-psychiatric comorbidity associated with Alzheimer's disease. QJM. https://doi.org/10.1093/qjmed/hcr118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.